MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Slides:

Advertisements

Similar presentations

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.

Advertisements

History of the randomized evidence on early breast cancer overall survival: Radiation vs no radiation after mastectomy L. Vakaet 2006.

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression Lindstrom LS et al. Proc SABCS 2010;Abstract S3-5.

Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.

Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.

Table S1: The results of ER, PgR, and HER2 status in IHC testing and mRNA expression in the full Consortium population (N=389) HER2 statusER status PgR.

Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.

Hallett, et al., - Supplementary Figure 1

MAP-tau expression in the Yale University Cohort

سرطان الثدي Breast Cancer

CD25 expression is associated with unfavorable clinical outcome.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Prognostic significance of DDB2 in ovarian cancer.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Figure 3 Summary of overall survival by Kaplan–Meier

AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Supplementary Figure 2 Shiota et al.

HOXB7 interacts with ERα and enhances expression of ER target genes.

(A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB.

Distinct molecular and clinical correlates of H3F3A mutation subgroups

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Progastrin expression in colonic tissues and Kaplan–Meier survival curves. Progastrin expression in colonic tissues and Kaplan–Meier survival curves. A,

Frequent alterations identified and potential actionability.

mTORC1 is required for malignant transformation in the Eμ-Myc model.

A, Overall survival of patients treated with CAR T cells (black line; n = 15). A, Overall survival of patients treated with CAR T cells (black line; n.

LINC00092 binds with PFKFB2 to promote ovarian cancer metastasis.

CXCL14-positive CAFs induce overexpression of LINC00092 in ovarian cancer. CXCL14-positive CAFs induce overexpression of LINC00092 in ovarian cancer. A,

Reduced BAI1 expression is associated with breast cancer patient survival. Reduced BAI1 expression is associated with breast cancer patient survival. A,

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Clinical outcomes resulting from.

EN1 expression in breast cancer and clinical outcome.

Somatic mutational rates and survival analysis of IBD-CRC.

ALDH1A3 expression levels are inversely correlated with the survival of patients with resectable mass-forming and advanced cholangiocarcinoma, respectively.

Kaplan–Meier curves for PFS and OS (for patients treated with anti-PD-1/PD-L1 monotherapy). Kaplan–Meier curves for PFS and OS (for patients treated with.

Mir-128 reduction in breast cancer tissues correlates chemotherapy resistance and poor patient survival. Mir-128 reduction in breast cancer tissues correlates.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.

HMQ1611 inhibited breast tumor growth in mice.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Clustering analysis of DTC-associated genes.

Representative images demonstrating LOH in breast cancer patients’ paired BM aspirate and primary tumors (T) at D14S62, D14S51, and D8S321, respectively.

Location of the ER mutations and frequencies per cohort.

Kaplan–Meier curves for RFS and OS by various marker groups.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Change in FES uptake in the tumor during fulvestrant treatment.

Association of overall survival and PAP-specific (A, B) and PA2024-specific (C, D) CTL activity at week 26 using categorical (tertile) analysis and continuous.

Possible outcomes of therapeutic treatments using the spiral model.

The CCR5+ population of SUM-159 cells is enriched with tumor-initiating cells. The CCR5+ population of SUM-159 cells is enriched with tumor-initiating.

Ki-67 and ERα immunostaining in the mammary gland.

Patient stratification using survival risk prediction and BCLC staging

A and B, linearity of the preamplification step shown by a similar expression pattern of ERα mRNA in four breast tumor samples pre– and post–linear amplification.

Progression and survival analysis.

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

MYC and LYN are coexpressed and have interdependent clinical outcomes.

Expression of TGFβ ligands in GBM

STK11/LKB1 mutations are a genomic determinant of poor clinical outcome with PD-1 axis blockade in PD-L1–positive nonsquamous NSCLC, regardless of KRAS.

Immunohistochemical determination of TIM-3 expression in ccRCC.

CD36 expression is coordinately regulated in multiple cellular compartments. CD36 expression is coordinately regulated in multiple cellular compartments.

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

DYNLRB1, AIMP1, and NPIPA1 expression correlate with survival in neuroblastoma. DYNLRB1, AIMP1, and NPIPA1 expression correlate with survival in neuroblastoma.

Isolation of large soft agar clones from HBEC3p53,KRAS and HBEC3p53,KRAS,MYC identifies tumorigenic and nontumorigenic clones and genome-wide mRNA expression.

GSN and DNMT1 expression are inversely correlated in a pattern associated with patient survival. GSN and DNMT1 expression are inversely correlated in a.

Presentation transcript:

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. The Kaplan–Meier plots of overall survival (OS) probability in endocrine therapy–treated breast cancer patients with ER-positive tumors (n = 1,208) expressing (A) HOXB7, (B) HOXB7 and HER2, and (C) HOXB7, HER2, and MYC. Kideok Jin et al. Cancer Discovery 2015;5:944-959 ©2015 by American Association for Cancer Research